Parnax Lab Ltd

Parnax Lab's capital structure shows a debt-to-equity ratio of 0.84, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 0.92, suggesting that its current liabilities slightly exceed its current assets. This is further supported by the risk assessment, which identifies liquidity as a medium concern, with a key flag indicating that net cash is negative after subtracting total debt. In terms of profitability, Parnax Lab's return on equity (ROE) is 13.86%, and its return on assets (ROA) is 6.07%. These figures are to be compared against the industry's preferred metrics, which typically emphasize high ROE and ROA for pharmaceutical firms. The company's operating income of INR 197.64 million and net income of INR 115.19 million reflect a healthy margin, although the gross profit margin of 45.7% (calculated from INR 858.08 million gross profit on INR 1.88 billion revenue) is in line with industry norms. The company's revenue is concentrated in a single segment, the trading of pharmaceuticals and medicinal products, which accounts for the entirety of its INR 1.88 billion in revenue. Geographically, the company's exposure is primarily to India, with no disclosed international revenue streams. This concentration may pose a risk in the event of domestic economic or regulatory changes. Parnax Lab's growth trajectory is modest, with the outlook for the current fiscal year (FY) and the next FY not showing significant revenue growth. The company's capital expenditure of INR -185.78 million indicates a reduction in investment in physical assets, which may signal a focus on cost optimization or a shift in strategic priorities. The risk assessment highlights a low dilution potential, with no immediate signs of equity dilution. However, the company's negative net cash position and the presence of long-term debt of INR 695.26 million could be a concern if not managed effectively. The company has not disclosed any recent equity issuance or ATM/shelf registration, which supports the low dilution risk rating. Recent events and filings do not indicate any material changes in the company's operations or financial position. The company's 10-K Risk Factors and other disclosures do not mention any significant legal or regulatory issues that could impact its operations in the near term.